Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers

Yang, Xin1; Wen, Xiaofeng1; Guo, Qin1; Zhang, Yunfeng3; Liang, Zhenxing1,2; Wu, Qian1,2; Li, Zhihao1,2; Ruan, Weimei5; Ye, Zhujia5; Wang, Hong5; Chen, Zhiwei5; Fan, Jian-Bing4,5; Lan, Ping1,2; Liu, Huashan1,2; Wu, Xianrui1,2

2022-12-01

10.1186/s13148-022-01383-8

Clinical Epigenetics   影响因子和分区

1868-7075

1868-7083

Background: Recurrence represents a well-known poor prognostic factor for colorectal cancer (CRC) patients. This study aimed to establish an effective prognostic prediction model based on noninvasive circulating tumor DNA methylation markers for CRC patients receiving radical surgery. Results: Two methylation markers (cg11186405 and cg17296166) were identified by Cox regression and receiver operating characteristics, which could classify CRC patients into high recurrence risk and low recurrence risk group. The 3-year disease-free survival was significantly different between CRC patients with low and high recurrence risk [Training set: hazard ratio (HR) 28.776, 95% confidence interval (CI) 3.594-230.400; P = 0.002; Validation set: HR 7.796, 95% CI 1.425-42.660, P = 0.018]. The nomogram based on the above two methylation markers and TNM stage was established which demonstrated robust prognostic prediction potential, as evidenced by the decision curve analysis result. Conclusions: A cell-free DNA methylation model consisting of two DNA methylation markers is a promising method for prognostic prediction in CRC patients.

Colorectal cancer DNA methylation Disease-free survival Prognostic prediction

SCI

英语

其他

National Natural Science Foundation of China["2017YFC1308800","2017YFC1309002"] ; Guangdong Natural Science Foundation["81870383","2020B1111170004"] ; Science and Technology Planning Project of Guangzhou City["82200569","2017A030313785"] ; Science and Technology Planning Project of Guangdong Province[2016A030310187] ; Key-Area Research and Development Program of Guangdong Province["201804010014","2015B020229001","20160916"] ; Scheme of Guangzhou Economic and Technological Development District for Leading Talents in Innovation and Entrepreneurship[2017B020226005] ; Scheme of Guangzhou for Leading Talents in Innovation and Entrepreneurship[2019B020229002] ; Scheme of Guangzhou for Leading Team in Innovation[2017-L152] ; National Key Clinical Discipline and the program of Guangdong Provincial Clinical Research Center for Digestive Diseases[2016007] ; China Postdoctoral Science Foundation[201909010010] ; Guangdong Basic and Applied Basic Research Foundation[2021M703723] ; [2021A1515111011]

Oncology ; Genetics & Heredity

Oncology ; Genetics & Heredity

WOS:000893065800003

BMC

Web of Science

1.Sun Yat sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, 26 Yuancun Erheng Rd, Guangzhou 510655, Guangdong, Peoples R China
2.Sun Yat sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, Guangzhou 510655, Guangdong, Peoples R China
3.Jinan Univ, Southern Univ Sci & Technol, Shenzhen Peoples Hosp,Dept Gen Surgery, Affiliated Hosp 1 Shenzhen Peoples Hosp,Clin Med, Shenzhen 518020, Guangdong, Peoples R China
4.Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Peoples R China
5.AnchorDx Med Co Ltd, Unit 502, 3rd Luoxuan Rd, Int Bio-Isl, Guangzhou 510300, Peoples R China

Yang, Xin,Wen, Xiaofeng,Guo, Qin,et al. Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers[J]. Clinical Epigenetics,2022,14(1).

Yang, Xin.,Wen, Xiaofeng.,Guo, Qin.,Zhang, Yunfeng.,Liang, Zhenxing.,...&Wu, Xianrui.(2022).Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers.Clinical Epigenetics,14(1).

Yang, Xin,et al."Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers".Clinical Epigenetics 14.1(2022).